跳至主要内容
临床试验/TCTR20181202002
TCTR20181202002终止4 期

A Randomized, Controlled Trial of Prulifloxacin as Switched Therapy after Intravenous Carbapenem in The Treatment of Acute Pyelonephritis Caused by Third Generation Cephalosporin Resistant Pathogens: A Pilot study

THAI MEIJI PHARMACEUTICAL CO., LTD.0 个研究点目标入组 30 人开始时间: 2018年12月2日最近更新:
适应症

试验速览

阶段
4 期
状态
终止
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 100 Years(—)
性别
All

入选标准

  • 1.aged older than 18 years
  • 2.Urine culture show 10,000 CFU/ml of third generation cephalosporin resistant pathogens. Causative bacteria are classified into susceptibility to ertapenem and prulifloxacin.
  • 3.signs and symptoms are not worsening after receiving empirical therapy.

排除标准

  • 1. Pregnancy and lactation
  • 2. History allergy to beta lactams or fluoroquinolones
  • 3. Treatment with antiretroviral drugs, immunosuppressive drugs or corticosteroids
  • 4. Need more than one antibiotic for treatment.
  • 5. Complete obstruction of the urinary tract need to surgery.
  • 6. Serious diseases lead to shorten lifespan no more than 72 hours.
  • 7. Neutropenia (Absolute neutrophil counts less than 500 cell/microliters)
  • 8. Creatinine clearance less than 20 ml/min

研究者

发起方
THAI MEIJI PHARMACEUTICAL CO., LTD.

相似试验

A Randomized, Controlled Trial of Prulifloxacin as... | 临床试验